Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
Ruddy KJ, Pitcher BN, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Annals Of Oncology 2012, 23: 3075-3081. PMID: 22767584, PMCID: PMC3501229, DOI: 10.1093/annonc/mds133.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast cancerMedication calendarOral cyclophosphamideStandard chemotherapyStage I-IIIB breast cancerSelf-reported adherenceCase report formsToxic effectsAdjuvant chemotherapyCALGB 49907Febrile neutropeniaOral CMFNode negativityOlder patientsStandard therapyMedian ageSuperior tolerabilityRandomized trialsCyclophosphamide dosesAverage adherenceOlder womenCyclophosphamideChemotherapyConsecutive days